Minerva Neurosciences, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | $0 | $0 |
| Operating income | -$15.1M | -$21.8M | -$23.1M | -$25.2M | -$45.4M |
| Operating expenses | $15.1M | $21.8M | $23.1M | $25.2M | $45.4M |
| Cash from operations | -$13.5M | -$19.6M | -$14.8M | -$24.6M | -$24.6M |
| Capital expenditure | — | — | — | $16,326 | — |
| Free cash flow | — | — | — | -$24.7M | — |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $98.0M | $37.1M | $56.9M | $55.1M | $77.1M |
| Total liabilities | $233.8M | $62.8M | $85.4M | $75.1M | $69.1M |
Shares outstanding 46.6M · Free float 87.9%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.